Shield Therapeutics plc – LSE:STX.L

Founder-led company

Shield Therapeutics stock price today

GBP 44.5
+41.8
+1548.15%
Financial Health
0
1
2
3
4
5
6
7
8
9

Shield Therapeutics stock price monthly change

+74.19%
month

Shield Therapeutics stock price quarterly change

+74.19%
quarter

Shield Therapeutics stock price yearly change

-59.09%
year

Shield Therapeutics key metrics

Market Cap
 21.50M
Enterprise value
 N/A
P/E
 N/A
EV/Sales
 N/A
EV/EBITDA
 N/A
Price/Sales
 N/A
Price/Book
 N/A
PEG ratio
 N/A
EPS
 -0.20
Revenue
 14.96M
EBITDA
 -51.88M
Income
 -67.17M
Revenue Q/Q
 N/A
Revenue Y/Y
 N/A
Profit margin
 0%
Oper. margin
 0%
Gross margin
 0%
EBIT margin
 0%
EBITDA margin
 -346.72%

Get more financial ratios!

  • Every financial ratio you might need

  • 10 years history

  • Forward ratios (Analysts estimates)

Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Shield Therapeutics stock price history

Shield Therapeutics stock forecast

Shield Therapeutics financial statements

Profit Margin

Shield Therapeutics plc (LSE:STX.L): Profit margin
Jun 2022 2.03M -11.78M -580.11%
Dec 2022 2.43M -28.66M -1176.6%
Jun 2023 3.51M -10.22M -290.84%
Dec 2023 6.98M -16.51M -236.41%
STX.L income statement history

Shield Therapeutics Financials Estimate

Shield Therapeutics plc (LSE:STX.L): Analyst Estimates
2027 89.12M 2.53M 2.85%

  • Analysts Price target

  • Financials & Ratios estimates

Show more

Debt to Assets

Shield Therapeutics plc (LSE:STX.L): Debt to assets
Jun 2022 35824000 3.25M 9.08%
Dec 2022 22074000 16.64M 75.41%
Jun 2023 41667000 14.56M 34.96%
Dec 2023 38279730 26.48M 69.19%
STX.L balance sheet history

Cash Flow

Shield Therapeutics plc (LSE:STX.L): Cash Flow
Jun 2022 -8.52M -1.30M 57K
Dec 2022 -9.08M -592K 7.28M
Jun 2023 -15.86M -1.33M 24.43M
Dec 2023 -13.83M -1.01M 15.68M
STX.L cash flow history

Shield Therapeutics alternative data

Shield Therapeutics
Employees

Shield Therapeutics plc (LSE:STX.L): Employee count
Aug 2023 27
Sep 2023 27
Oct 2023 27
Nov 2023 27
Dec 2023 27
Jan 2024 27
Feb 2024 27
Apr 2024 27
May 2024 27
Jun 2024 27
Jul 2024 73

Shield Therapeutics other data

Shield Therapeutics
Executives

Insider Compensation
Mr. Christian Schweiger M.D., Ph.D. (1967) Co-Founder & Non Executive Director
 $20,000

Frequently Asked Questions (FAQ)

  • What's the price of Shield Therapeutics stock today?

    One share of Shield Therapeutics stock can currently be purchased for approximately $44.5.

  • When is Shield Therapeutics's next earnings date?

    Unfortunately, Shield Therapeutics's (STX.L) next earnings date is currently unknown.

  • Does Shield Therapeutics pay dividends?

    No, Shield Therapeutics does not pay dividends.

  • How much money does Shield Therapeutics make?

    Shield Therapeutics has a market capitalization of 21.50M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 192.93% to 13.09M US dollars.

  • What is Shield Therapeutics's stock symbol?

    Shield Therapeutics plc is traded on the LSE under the ticker symbol "STX.L".

  • What is Shield Therapeutics's primary industry?

    Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.

  • How do i buy shares of Shield Therapeutics?

    Shares of Shield Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Shield Therapeutics's key executives?

    Shield Therapeutics's management team includes the following people:

    • Mr. Christian Schweiger M.D., Ph.D. Co-Founder & Non Executive Director(age: 58, pay: $20,000)

  • Is Shield Therapeutics founder-led company?

    Yes, Shield Therapeutics is a company led by its founder Mr. Christian Schweiger M.D., Ph.D..

  • How many employees does Shield Therapeutics have?

    As Jul 2024, Shield Therapeutics employs 73 workers, which is 170% more then previous month and 170% more then previous quarter.

  • When Shield Therapeutics went public?

    Shield Therapeutics plc is publicly traded company for more then 9 years since IPO on 26 Feb 2016.

  • What is Shield Therapeutics's official website?

    The official website for Shield Therapeutics is shieldtherapeutics.com.

  • How can i contact Shield Therapeutics?

    Shield Therapeutics can be reached via phone at +44 191 511 8500.

Shield Therapeutics company profile:

Shield Therapeutics plc

shieldtherapeutics.com
Exchange:

LSE

Full time employees:

73

Industry:

Drug Manufacturers - Specialty & Generic

Sector:

Healthcare

Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of clinical stage pharmaceuticals to treat unmet medical needs. The company's lead product is Accrufer/Feraccru, a non-salt based oral therapy for the treatment of iron deficiency with or without anemia in adults. It also develops PT20, a novel iron-based phosphate binder that has completed its Phase II pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company was founded in 2008 and is based in Gateshead, the United Kingdom.

+44 191 511 8500
Northern Design Centre
Gateshead, NE8 3DF

:
ISIN: GB00BYV81293
CUSIP: G8123P102